Northern Trust’s Inhibikase Therapeutics IKT Stock Holding History

Northern Trust’s Portfolio IKT Stock Details IKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.21M	Buy	718,800 +396,080	+123%	+$703K	﹤0.01%	3246
2025 Q4	$662K	Sell	322,720 -51,616	-14%	-$82.1K	﹤0.01%	3553
2025 Q3	$606K	Sell	374,336 -18,380	-5%	-$31.8K	﹤0.01%	3585
2025 Q2	$766K	Buy	392,716 +328,705	+514%	+$644K	﹤0.01%	3509
2025 Q1	$140K	Hold	64,011	–	–	﹤0.01%	4036
2024 Q4	$208K	Buy	+64,011	New	+$160K	﹤0.01%	3978
2023 Q2	–	Sell	-4,812	Closed	-$19K	–	4558
2023 Q1	$19K	Hold	4,812	–	–	﹤0.01%	4457
2022 Q4	$14.4K	Hold	4,812	–	–	﹤0.01%	4535
2022 Q3	$26K	Hold	4,812	–	–	﹤0.01%	4497
2022 Q2	$21K	Hold	4,812	–	–	﹤0.01%	4616
2022 Q1	$43K	Hold	4,812	–	–	﹤0.01%	4562
2021 Q4	$42K	Buy	4,812 +2,193	+84%	+$24.2K	﹤0.01%	4618
2021 Q3	$30K	Buy	+2,619	New	+$35.4K	﹤0.01%	4590

Other funds holding IKT

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Northern Trust's IKT Position: Q1 2026 in Review

Northern Trust increased its Inhibikase Therapeutics (IKT) stake by 123% in Q1 2026, buying an estimated $703K and bringing the position to 718,800 shares worth $1.21M. The position accounts for ﹤0.01% of the portfolio, ranked #3246.

Northern Trust first reported a position in IKT in Q3 2021 and has held it in 13 quarters since. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

Northern Trust held 718,800 shares of Inhibikase Therapeutics worth $1.21M as of Q1 2026.
Northern Trust bought 396,080 Inhibikase Therapeutics shares in Q1 2026, an estimated $703K.
Inhibikase Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3246 holding.
Northern Trust first reported a position in Inhibikase Therapeutics in Q3 2021 and has held it in 13 quarters since.
104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.